Results 161 to 170 of about 14,520 (202)
Fulvestrant (‘Faslodex’): Current and future role in breast cancer management
Critical Reviews in Oncology/Hematology, 2006 Fulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors.
Anthony Howell
exaly +2 more sources
Oncogene, 2010 Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies.
X Rao, Matthew E Burow, Mircea Ivan
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Investigational Drugs, 2002
Fulvestrant, a novel oestrogen receptor (ER) downregulator, is a pure anti-oestrogen which completely blocks the trophic actions of oestrogens without exerting any partial agonist effects. It reduces expression of oestrogen receptor, progesterone receptor and proliferative and cell turnover indices. The drug is well-tolerated with minimal systemic side
Kwok Leung, Cheung, John F R, Robertson
openaire +2 more sources
Fulvestrant, a novel oestrogen receptor (ER) downregulator, is a pure anti-oestrogen which completely blocks the trophic actions of oestrogens without exerting any partial agonist effects. It reduces expression of oestrogen receptor, progesterone receptor and proliferative and cell turnover indices. The drug is well-tolerated with minimal systemic side
Kwok Leung, Cheung, John F R, Robertson
openaire +2 more sources
European Journal of Cancer, 2007 Fulvestrant (Faslodex™) reduces markers of hormone sensitivity and proliferation in postmenopausal women. This Phase II double-blind, randomised, multicentre study compared the effects of a single 250mg intramuscular dose of fulvestrant and placebo 14–21
J F R Robertson +2 more
exaly +2 more sources
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs [PDF]
Cancer Letters, 2014 The human homologue of mouse double minute 2 (MDM2) is overexpressed in tumors and contributes to tumorigenesis through inhibition of p53 activity. We investigated the effect of the anti-estrogen fulvestrant on MDM2 expression and sensitivity of estrogen
Daniel Medina +2 more
exaly +2 more sources
The future of fulvestrant (‘Faslodex’)
Cancer Treatment Reviews, 2005Changes in clinical practice regarding favoured first-line and adjuvant treatments for postmenopausal women with advanced breast cancer (ABC) mean that it is becoming increasingly important to identify agents that are effective following aromatase inhibitor (AI) failure as well as tamoxifen failure. Fulvestrant ("Faslodex") is a new oestrogen receptor (
openaire +2 more sources
Hospital Pharmacy, 2002
The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Dominic A. Solimando, J. Aubrey Waddell
openaire +1 more source
The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Dominic A. Solimando, J. Aubrey Waddell
openaire +1 more source